Gilteritinib Fumarate Drug Asset Due Diligence Report 2026

This Gilteritinib Fumarate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

106

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Gilteritinib Fumarate can convert its Small molecule drug profile and AXL x FLT3 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Gilteritinib Fumarate (query alias: Gilteritinib Fumarate)
Modality / target	Small molecule drug; AXL x FLT3; AXL inhibitors, FLT3 inhibitors
Highest global status	Approved
Originator	Astellas Pharma, Inc.
Active developers	Astellas Pharma, Inc., Astellas Pharma Global Development, Inc., Astellas Pharma Europe Ltd.

The MCP disease footprint includes Acute Myeloid Leukemia, FLT3 positive Acute Myeloid Leukemia, Anemia, Refractory, With Excess of Blasts. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07463651	Phase 3	Recruiting	594	Measurable residual disease recurrence-free survival (MRD-RFS)
NCT07548710	Phase 2	Recruiting	205	Composite Complete Remission
ChiCTR2600120648	Not Applicable	Recruiting	65	Overall response rate

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

GILTERITINIB VERSUS MIDOSTAURIN IN PATIENTS WITH NEWLY DIAGNOSED FLT3-MUTATED ACUTE MYELOID LEUKEMIA ELIGIBLE FOR INTENSIVE THERAPY: RESULTS FROM THE PHASE 3 HOVON156/AMLSG28-18/PASHA TRIAL

Phase 3; n=768; evaluation: Negative. Reported fields: mOS = NR ; mOS = NR

FLT3 inhibitors across the allogeneic transplant continuum in FLT3-mutated acute myeloid leukemia: A systematic review and meta-analysis.

Phase 2/3; n=333; evaluation: Positive. Reported fields: -; Composite complete remission = 54.0 %

FLT3 inhibitors in acute myeloid leukemia: A network meta-analysis of phase III trials.

Phase 3; n=not disclosed; evaluation: Positive. Reported fields: EFS: HR = 0.78(95.0% CI, 0.63 - 0.96); HR = 0.64(95.0% CI, 0.49 - 0.83); EFS: HR = 0.78(95.0% CI, 0.63 - 0.96); HR = 0.64(95.0% CI, 0.49 - 0.83); EFS: HR = 0.78(95.0% CI, 0.63 - 0.96); HR = 0.64(95.0% CI, 0.49 - 0.83)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Gilteritinib Fumarate addresses Acute Myeloid Leukemia, FLT3 positive Acute Myeloid Leukemia, Anemia, Refractory, With Excess of Blasts. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2020-12-21	A research collaboration between Astellas and Kotobuki Pharmaceutical Co., Ltd. found that Gilteritinib	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO